PL02.11 Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study
Luis Paz-Ares
1
,
Y. Chen
2
,
N. Reinmuth
3
,
Katsuyuki Hotta
4
,
D Trukhin
5
,
G Statsenko
6
,
Maximilian Johannes Hochmair
7
,
Mustafa Ozguroglu
8
,
J.H. Ji
9
,
O Voitko
10
,
A Poltoratskiy
11
,
Santiago Ponce
1
,
F VERDERAME
12
,
L Havel
13
,
Igor Bondarenko
14
,
A. Kazarnowicz
15
,
Gy�rgy Losonczy
16
,
Nikolay Conev
17
,
J ARMSTRONG
18
,
N. Byrne
18
,
Norah J Shire
19
,
H. Jiang
19
,
J. Goldman
20
1
2
Cancer and Hematology Centers of Western Michigan, Grand Rapids, MI, US
|
3
Asklepios Lung Clinic, Munich-Gauting/DE
|
5
Odesa National Medical University, Odesa/UA
|
6
Omsk Regional Cancer Center, Omsk/RU
|
7
Department of Respiratory and Critical Care Medicine, Krankenhaus Nord – Klinik Floridsdorf, Vienna/AT
9
10
Kyiv City Clinical Oncological Centre, Kiev/UA
|
12
Ao Ospedali Riuniti Po Vincenzo Cervello, Palermo/IT
|
14
Dnipropetrovsk Medical Academy, Dnipro/UA
|
15
Tuberculosis and Lung Disease Hospital, Olsztyn/PL
|
17
Clinic of Medical Oncology, Umhat St Marina, Varna/BG
19
AstraZeneca, Gaithersburg, MD, US
|
Publication type: Journal Article
Publication date: 2019-10-21
scimago Q1
wos Q1
SJR: 7.948
CiteScore: 34.9
Impact factor: 20.8
ISSN: 15560864, 15561380
Oncology
Pulmonary and Respiratory Medicine
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
3
|
|
|
Journal of Thoracic Oncology
3 publications, 17.65%
|
|
|
Medicine (United States)
1 publication, 5.88%
|
|
|
Therapeutic Advances in Medical Oncology
1 publication, 5.88%
|
|
|
Nature Cancer
1 publication, 5.88%
|
|
|
Nature Reviews Clinical Oncology
1 publication, 5.88%
|
|
|
Cancer Immunology, Immunotherapy
1 publication, 5.88%
|
|
|
Revue des Maladies Respiratoires Actualites
1 publication, 5.88%
|
|
|
Clinics in Chest Medicine
1 publication, 5.88%
|
|
|
The Lancet Oncology
1 publication, 5.88%
|
|
|
Journal of Clinical Neurology (Korea)
1 publication, 5.88%
|
|
|
Advances in Clinical Medicine
1 publication, 5.88%
|
|
|
Translational Cancer Research
1 publication, 5.88%
|
|
|
Journal of Cancer Research and Clinical Oncology
1 publication, 5.88%
|
|
|
1
2
3
|
Publishers
|
1
2
3
4
5
6
|
|
|
Elsevier
6 publications, 35.29%
|
|
|
Springer Nature
4 publications, 23.53%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
1 publication, 5.88%
|
|
|
SAGE
1 publication, 5.88%
|
|
|
Korean Neurological Association
1 publication, 5.88%
|
|
|
Hans Publishers
1 publication, 5.88%
|
|
|
AME Publishing Company
1 publication, 5.88%
|
|
|
1
2
3
4
5
6
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
17
Total citations:
17
Citations from 2024:
1
(5.88%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Paz-Ares L. et al. PL02.11 Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study // Journal of Thoracic Oncology. 2019. Vol. 14. No. 10. p. S7-S8.
GOST all authors (up to 50)
Copy
Paz-Ares L., Chen Y., Reinmuth N., Hotta K., Trukhin D., Statsenko G., Hochmair M. J., Ozguroglu M., Ji J., Voitko O., Poltoratskiy A., Ponce S., VERDERAME F., Havel L., Bondarenko I., Kazarnowicz A., Losonczy G., Conev N., ARMSTRONG J., Byrne N., Shire N. J., Jiang H., Goldman J. PL02.11 Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study // Journal of Thoracic Oncology. 2019. Vol. 14. No. 10. p. S7-S8.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1016/j.jtho.2019.08.061
UR - https://doi.org/10.1016/j.jtho.2019.08.061
TI - PL02.11 Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study
T2 - Journal of Thoracic Oncology
AU - Paz-Ares, Luis
AU - Chen, Y.
AU - Reinmuth, N.
AU - Hotta, Katsuyuki
AU - Trukhin, D
AU - Statsenko, G
AU - Hochmair, Maximilian Johannes
AU - Ozguroglu, Mustafa
AU - Ji, J.H.
AU - Voitko, O
AU - Poltoratskiy, A
AU - Ponce, Santiago
AU - VERDERAME, F
AU - Havel, L
AU - Bondarenko, Igor
AU - Kazarnowicz, A.
AU - Losonczy, Gy�rgy
AU - Conev, Nikolay
AU - ARMSTRONG, J
AU - Byrne, N.
AU - Shire, Norah J
AU - Jiang, H.
AU - Goldman, J.
PY - 2019
DA - 2019/10/21
PB - Elsevier
SP - S7-S8
IS - 10
VL - 14
SN - 1556-0864
SN - 1556-1380
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2019_Paz-Ares,
author = {Luis Paz-Ares and Y. Chen and N. Reinmuth and Katsuyuki Hotta and D Trukhin and G Statsenko and Maximilian Johannes Hochmair and Mustafa Ozguroglu and J.H. Ji and O Voitko and A Poltoratskiy and Santiago Ponce and F VERDERAME and L Havel and Igor Bondarenko and A. Kazarnowicz and Gy�rgy Losonczy and Nikolay Conev and J ARMSTRONG and N. Byrne and Norah J Shire and H. Jiang and J. Goldman},
title = {PL02.11 Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study},
journal = {Journal of Thoracic Oncology},
year = {2019},
volume = {14},
publisher = {Elsevier},
month = {oct},
url = {https://doi.org/10.1016/j.jtho.2019.08.061},
number = {10},
pages = {S7--S8},
doi = {10.1016/j.jtho.2019.08.061}
}
Cite this
MLA
Copy
Paz-Ares, Luis, et al. “PL02.11 Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study.” Journal of Thoracic Oncology, vol. 14, no. 10, Oct. 2019, pp. S7-S8. https://doi.org/10.1016/j.jtho.2019.08.061.